source
- Alterome reports early Phase 1 data for KRAS-targeted therapy in pancreatic, lung and colon cancersAlterome has unveiled preliminary Phase 1 data for its experimental KRAS-targeted therapy. The drug is designed to hit a spectrum of KRAS mutations that drive several solid tumours. The early stud…
- Teva appoints interim R&D head as Eric Hughes departsTeva announced that its global research and development leader and chief medical officer, Eric Hughes, has left the company. Hughes, who joined Teva in 2022 after a senior role at Vertex, will be s…